Views & Analysis | Perspectives on pharma industry issues

Oncology

Australia, CAR-T therapy, and solid tumours

Bev Menner, chief executive officer at Cell Therapies Pty Ltd, discusses CAR-T therapies for solid tumours and Australian and APAC R&D more generally.

Market Access

Two business hands outstretched, one weighing cash, the other drugs, for balance

What the revised 340B rebate pilot programme means for pharm...

While the scope of the revised pilot is limited, it may be a harbinger for a broader policy shift.

Digital

IQVIA Technologies sponsored podcast, with Updesh Dosanjh

AI-enabled pharmacovigilance, with Updesh Dosanjh

Updesh Dosanjh, IQVIA commercialisation lead for safety technology, discusses how and why the role of AI in pharmacovigilance is changing.

Digital

Two female silhouettes in a city office overlook the urban landscape below

How female leadership can benefit industry

Day One Strategy’s founding partners Abigail Stuart and Hannah Mann share the benefits female leadership can bring to industry.

Patients

Maintenance: The underexamined half of the GLP-1 story

GLP-1 treatments have historically had an exit problem, as appetite suppression stops when the medication stops.

Articles

Time to Evolve! Overview of eyeforpharma’s ‘7th annual e-mar...

Ángel González provides an overview of the topics addressed at eyeforpharma’s recent ‘7th annual e-marketing Europe and mobile 2012’ event. Time to evolve - this was the claim used by the organization as the forefront message of this international event.

Articles

Beyond clinician support: how to successfully launch paradig...

David Lee and Peter Ehrhardt explore the factors medical technology manufacturers face when pricing paradigm-shifting technologies, looking at past pharma product launches for insights into the current process. Paradigm-shifting technologies, defined as innovations that change the standard of care in a significant way, are the lifeblood of the medical technology industry…

Articles

Personalised medicine: a view from Roche

We interview Dr Horst Kramer of Roche on his definition of personalised medicine, the importance of clear communication in this area and the need for reliable diagnostics. Personalised medicine has received a lot of hype in the media. Over-promising and exaggerations have led to…

Sales & Marketing

Accelerating growth through strategic investment in healthca...

CEVA FORPATIENTS at Rockingham, UK will offer the healthcare supply chain a new, sustainably designed multi-user site.

Sales & Marketing

The patient communication crisis pharma can no longer ignore

Industry's significant investments in patient engagement are only effective if patients trust the communication enough to answer in the first place.

Digital

AI-enabled pharmacovigilance, with Updesh Dosanjh

Updesh Dosanjh, IQVIA commercialisation lead for safety technology, discusses how and why the role of AI in pharmacovigilance is changing.

Digital

How female leadership can benefit industry

Day One Strategy’s founding partners Abigail Stuart and Hannah Mann share the benefits female leadership can bring to industry.

Market Access

What the revised 340B rebate pilot programme means for pharm...

While the scope of the revised pilot is limited, it may be a harbinger for a broader policy shift.

Market Access

$100 notes in pill bottle on aquamarine background with spilled pills

How new PBM transparency rules will alter drug pricing

The complex drug pricing ecosystem means all stakeholders are scrambling to understand how the new regulations and PBMs’ adjustments will impact them.

Oncology

Australia, CAR-T therapy, and solid tumours

Bev Menner, chief executive officer at Cell Therapies Pty Ltd, discusses CAR-T therapies for solid tumours and Australian and APAC R&D more generally.

Oncology